ExpreS2ion CEO to BioStock: “Compelling preclinical package gives us confidence”

Based on its proprietary protein expression platform, ExpreS2ion Biotech advances its ES2B-C001 breast cancer vaccine candidate toward clinical studies. A SEK 60 million rights issue is underway to fund this pivotal step. CEO Bent U. Frandsen discussed the current development and the future plans ahead with BioStock.

Read the full article at biostock.se:

https://www.biostock.se/2024/06/expres2ion-ceo-compelling-preclinical-package-gives-us-confidence/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se